Reuters logo
a month ago
BRIEF-Oncology Venture and Eisai forge exclusive global license agreement for clinical stage oncology drug PARP inhibitor E7449 / 2X-121
July 7, 2017 / 12:54 PM / a month ago

BRIEF-Oncology Venture and Eisai forge exclusive global license agreement for clinical stage oncology drug PARP inhibitor E7449 / 2X-121

July 7 (Reuters) - Eisai Co Ltd

* ‍Oncology Venture - Co entered into exclusive global license agreement with Eisai Inc. for Eisai's phase 2 parp inhibitor E7449 - now called 2X-121​

* Oncology Venture​ - ‍further terms of agreement were not disclosed Oncology Venture​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below